Literature DB >> 23267128

LATS2 is a modulator of estrogen receptor alpha.

Lei Cheng Lit1, Susan Scott, Hua Zhang, Justin Stebbing, Andrew Photiou, Georgios Giamas.   

Abstract

BACKGROUND: Estrogen Receptor α (ERα), a member of the nuclear receptor superfamily of transcription factors, plays a central role in breast cancer development. More than two-thirds of patients with breast cancer are ERα-positive; however, a proportion becomes resistant. Phosphorylation of ERα is one of the mechanisms associated with resistance to endocrine therapy. In a kinome screen, we have identified the large tumor suppressor homolog-2 (LATS2) as a potential kinase, acting on ERα.
MATERIALS AND METHODS: The role of LATS2 on activation of ERα transcription and its functional consequences was examined by various molecular and cellular biology techniques.
RESULTS: LATS2 co-localises with ERα in the nucleus. LATS2-silencing increases expression of ERα-regulated genes and inhibits proliferation. At the protein level, inhibition of LATS2 reduces the expression of cyclin-D1 and Nuclear Receptor Co-Repressor (NCoR) while increasing the expression of p27.
CONCLUSION: Identifying novel kinases which modulate ERα activity is relevant to therapeutics. LATS2 modulates ERα-regulated gene transcription, through direct and/or indirect interactions with ERα.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23267128

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  11 in total

Review 1.  The LATS1 and LATS2 tumor suppressors: beyond the Hippo pathway.

Authors:  Noa Furth; Yael Aylon
Journal:  Cell Death Differ       Date:  2017-06-23       Impact factor: 15.828

Review 2.  Mechanical Regulation of Transcription: Recent Advances.

Authors:  Kaustubh Wagh; Momoko Ishikawa; David A Garcia; Diana A Stavreva; Arpita Upadhyaya; Gordon L Hager
Journal:  Trends Cell Biol       Date:  2021-03-09       Impact factor: 20.808

3.  Melatonin and Hippo Pathway: Is There Existing Cross-Talk?

Authors:  Federica Lo Sardo; Paola Muti; Giovanni Blandino; Sabrina Strano
Journal:  Int J Mol Sci       Date:  2017-09-06       Impact factor: 5.923

Review 4.  Targeting the Hippo Pathway for Breast Cancer Therapy.

Authors:  Liqing Wu; Xiaolong Yang
Journal:  Cancers (Basel)       Date:  2018-11-05       Impact factor: 6.639

5.  Comprehensive Transcriptomic Analysis Reveals Dysregulated Competing Endogenous RNA Network in Endocrine Resistant Breast Cancer Cells.

Authors:  Liang Gao; Kunwei Shen; Ni Yin; Min Jiang
Journal:  Front Oncol       Date:  2020-11-24       Impact factor: 6.244

6.  RASSF1A-Mediated Suppression of Estrogen Receptor Alpha (ERα)-Driven Breast Cancer Cell Growth Depends on the Hippo-Kinases LATS1 and 2.

Authors:  Sven Roßwag; Jonathan P Sleeman; Sonja Thaler
Journal:  Cells       Date:  2021-10-24       Impact factor: 6.600

Review 7.  Drug-Resistant Breast Cancer: Dwelling the Hippo Pathway to Manage the Treatment.

Authors:  Simran Kaur; Mohammad Zeeshan Najm; Mohammad Aasif Khan; Naseem Akhter; Vyas M Shingatgeri; Mudra Sikenis; Abdulaziz A Aloliqi
Journal:  Breast Cancer (Dove Med Press)       Date:  2021-12-14

8.  Functional Genomics Identifies Tis21-Dependent Mechanisms and Putative Cancer Drug Targets Underlying Medulloblastoma Shh-Type Development.

Authors:  Giulia Gentile; Manuela Ceccarelli; Laura Micheli; Felice Tirone; Sebastiano Cavallaro
Journal:  Front Pharmacol       Date:  2016-11-30       Impact factor: 5.810

9.  LATS1 and LATS2 suppress breast cancer progression by maintaining cell identity and metabolic state.

Authors:  Noa Furth; Ioannis S Pateras; Ron Rotkopf; Vassiliki Vlachou; Irina Rivkin; Ina Schmitt; Deborah Bakaev; Anat Gershoni; Elena Ainbinder; Dena Leshkowitz; Randy L Johnson; Vassilis G Gorgoulis; Moshe Oren; Yael Aylon
Journal:  Life Sci Alliance       Date:  2018-10-30

10.  FOXC1 Regulation of miR-31-5p Confers Oxaliplatin Resistance by Targeting LATS2 in Colorectal Cancer.

Authors:  Hsi-Hsien Hsu; Wei-Wen Kuo; Hui-Nung Shih; Sue-Fei Cheng; Ching-Kuo Yang; Ming-Cheng Chen; Chuan-Chou Tu; Vijaya Padma Viswanadha; Po-Hsiang Liao; Chih-Yang Huang
Journal:  Cancers (Basel)       Date:  2019-10-16       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.